Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Study ID
NCT06613009
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • IBI3009 — DRUG
    Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3009)

Study Details

The main purpose of this study is to evaluate the safety and tolerability of IBI3009 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) of IBI3009.

Key Dates

First listed
Sep 25, 2024
Start date
Dec 30, 2024
Status verified
Feb 2025
Primary completion
Aug 30, 2027
Completion
Aug 30, 2027

Study Design

Enrollment
190 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: IBI3009

Primary Outcome Measure

Numbers of subjects with adverse events [ Time Frame: Up to 3 years ]

Central Contacts

Find similar trials

Nationwide
Lung cancer trialsOncology trialsLung oncology trialsLung disease trials

Related Studies